|
XENE Xenon Pharmaceuticals Inc 1582313 |
| Income Statement |
|
Net Income
|
2026-06-30
|
$-110,736,000.00 |
| Balance Sheet |
|
Current Assets
|
$945,868,000.00 |
|
Assets
|
$1,295,772,000.00 |
|
Current Liabilities
|
$45,009,000.00 |
|
Liabilities
|
$53,376,000.00 |
|
Equity
|
$1,242,396,000.00 |
|
Shares Out
|
96752884.00 |
| Cash Flow Statement |
|
Operating Cash Flow
|
$-184,287,000.00 |
|
Investing Cash Flow
|
$-738,520,000.00 |
| Market Analysis |
Market Cap
|
$5,779,049,761.32 |
|
Price
|
$59.73 |
|
BVPS
|
12.84 |
|
PB
|
4.65 |
|
EPS
|
-1.11 |
|
FCF
|
$-184,695,000.00 |
|
| Dividends |
|
Dividend Data Last Updated
|
2026-09-01 09:32:23 |
|
|
| Earnings |
|
Earnings Last Updated
|
2026-09-14 10:01:15 |
|
| Jan |
Feb |
Mar |
|
|
|
|
2026-02-26 |
-1.31 |
|
| Apr |
May |
Jun |
|
|
|
|
2026-05-07 |
-1.17 |
|
| Jul |
Aug |
Sep |
|
|
|
|
2025-08-11 |
1.07 |
|
| Oct |
Nov |
Dec |
|
|
|
|
2025-11-03 |
-1.15 |
|
|
Find a discrepancy? The most accurate way to find company fundamental data is to view XENE documents filed with the SEC.
XENE Filings
Clear
